Cable Viewer

Currently released so far... 12850 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01 2011/05/02 2011/05/03 2011/05/04 2011/05/05 2011/05/06 2011/05/07 2011/05/08 2011/05/09 2011/05/10 2011/05/11 2011/05/12 2011/05/13 2011/05/14 2011/05/15 2011/05/16 2011/05/17 2011/05/18 2011/05/19 2011/05/20 2011/05/21 2011/05/22

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 94 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/05 1985/06
1986/05
1987/06
1988/01 1988/03 1988/07
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/03 1992/06 1992/09 1992/12
1993/01 1993/10
1994/12
1996/07 1996/11
1997/06 1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/09 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/08 2002/09 2002/11 2002/12
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown Consulate Fukuoka
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata Consulate Karachi
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy Niamey Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples Consulate Naha
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sapporo Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
AE AEMR AORC APER AR AF ASEC AG AFIN AMGT APECO AS AMED AER ADCO AVERY AU AM APEC ABUD AGRICULTURE ASEAN ACOA AJ AO ABLD ADPM AY ASCH AFFAIRS AA AC ARF AFU AFGHANISTAN AINF AODE AMG ATPDEA AGAO ASECKFRDCVISKIRFPHUMSMIGEG AID AL AORL ADM AFSI AFSN ASUP AN AIT ANET ASIG AGMT ADANA AADP ACS AGR AMCHAMS AECL ACAO AUC AND ATRN ALOW APCS AORG AROC ACABQ AX AMEX AZ ARM AQ ATFN AMBASSADOR ACBAQ ASEX
BR BA BRUSSELS BG BEXP BO BM BBSR BU BL BK BT BD BMGT BY BX BTIO BB BH BF BP BWC BN BTIU BIDEN BE BILAT BC
CA CJAN CASC CS CO CH CI CD CVIS CR CU CN CY CONDOLEEZZA CE CG CMGT CF CPAS CDC CW CJUS CTM CM CFED CODEL CWC CBW CAN CLMT CBC CONS COUNTERTERRORISM CIA CDG CIC COUNTER CT CNARC CACM CB CV CIDA CLINTON CHR COE CIS CBSA CEUDA CAC CL CACS CAPC COM CARSON CTR CROS COPUOS CICTE CYPRUS COUNTRY CBE CKGR CVR CITEL CLEARANCE CARICOM CSW CITT CDB
DS DJ DEFENSE DR DA DTRA DEA DHS DO DEAX DAO DCM DE DOD DOMESTIC DK DPRK DEPT DISENGAGEMENT DOE
ECON EAID EINV EFIN EG EAIR EU EC ENRG EPET EAGR ELAB ETTC ELTN EWWT ETRD EUN ER ECIN EMIN EIND ECPS EZ EN ECA ET EFIS ENGR EINVETC ECONCS ES EI ECONOMIC ELN EINT EPA ETRA EXTERNAL ESA ETRDEINVECINPGOVCS EAIG EUR EK EUMEM EUREM EUC ENERG ERD EFTA ETRC ETRN EINVECONSENVCSJA EEPET EUNCH ESENV ENNP ENVI ECINECONCS ELECTIONS ENVR ENIV ETRO ETRDECONWTOCS ECUN EXIM EFINECONCS ERNG ECONOMY EINVEFIN ETC EAP EINN EXBS ENGY ECONOMICS EIAR EINDETRD ECONEFIN EURN EDU ETRDEINVTINTCS ECIP EFIM EAIDS EREL
FJ FI FR FTA FTAA FBI FAC FM FREEDOM FDA FARC FAO FO FOR FMLN FISO FAS FOREIGN FINANCE FINR FOI
GM GG GLOBAL GR GV GA GE GH GTIP GT GZ GAERC GOI GCC GOV GY GANGS GERARD GTMO GL GF GAZA
HUMAN HO HA HK HR HU HURI HILLARY HYMPSK HSTC HEBRON HUMOR HI
IC IR IN IT ICAO IS IZ IAEA IV IIP ICRC IWC IRS IQ IMO ILC IMF ILO IF ITPHUM IL IO ID ISRAEL IACI INMARSAT IRAQI IPR ICTY ICJ INDO IA IDA IBRD IAHRC ISLAMISTS IGAD ITU ITF INRA INRO INRB ITALY IBET INTELSAT ISRAELI IDP ICTR ITRA IRC IEFIN ITPGOV ITALIAN INTERNAL INTERPOL IEA INR IZPREL IRAJ
JA JP JO JM JOSEPH JUS JAMES JOHN JOHNNIE
KPAO KCOR KCRM KSCA KTFN KU KDEM KNNP KJUS KWMN KTIP KPAL KPKO KWWMN KWBG KISL KN KGHG KOMC KSTC KIPR KFLU KIDE KSAF KSEO KBIO KHLS KAWC KUNR KIRF KGIC KRAD KV KGIT KZ KE KCIP KTIA KFRD KHDP KSEP KMPI KG KMDR KTDB KS KSPR KHIV KCOM KAID KOM KRVC KICC KBTS KSUM KOLY KIRC KDRG KCRS KNPP KSTH KWNM KRFD KVIR KLIG KFLO KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KVPR KTEX KTER KRGY KCFE KREC KR KPAONZ KIFR KOCI KBTR KMCA KGCC KACT KMRS KAWK KSAC KWMNCS KNEI KPOA KFIN KWAC KNAR KPLS KPAK KSCI KPRP KOMS KBCT KPWR KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KRIM KDDG KPRV KCGC KPAI KFSC KMFO KID KMIG KVRP KNSD KMOC KTBT KHSA KENV KCMR KWMM KO KX KCRCM KNUP KNUC KNNPMNUC KERG KTLA KCSY KTRD KJUST KRCM KCFC KCHG KREL KFTFN KDEMAF KICA KHUM KSEC KPIN KESS KDEV
LY LE LG LH LABOR LI LO LA LU LOG LTTE LAB LT
MX MARR MTCRE MNUC MASS MOPS MCAP MO MA MR MAPS MD MV MY MP ML MILITARY MEPN MARAD MDC MU MEPP MIL MAPP MZ MT MASSMNUC MK MTCR MUCN MAS MEDIA MAR MI MQADHAFI MPOS MG MPS MW MC MASC MTRE MRCRE MOPPS MTS MLS MILI MEPI MEETINGS MERCOSUR MCC MIK
NZ NL NATO NU NI NG NO NP NK NDP NPT NSF NR NAFTA NATOPREL NS NEW NA NE NSSP NSC NH NV NPA NSFO NT NW NASA NSG NORAD NATIONAL NPG NGO NIPP NZUS NC NRR NAR
OTRA OREP OPIC OIIP OAS OVIP OEXC ODIP OFDP OPDC OPRC OSCE OECD OPCW OSCI OMIG OVP OIE ON OCII OPAD OBSP OFFICIALS OES OCS OIC OHUM OTR OSAC OFDA
PGOV PREL PHUM PTER PINR PK PINS PARM PA PHALANAGE PARTY PROP PM PBTS PDEM PECON PL PE PREF PO POL PSOE PHSA PAK PY PLN PMAR PHUH PBIO PF PHUS PTBS PU PNAT POLITICAL PARTIES PCUL PGGV PAO PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PAS PGIV PHUMPREL POGOV PEL PP PINL PBT PG PINF PRL PALESTINIAN PSEPC POSTS PDOV PAHO PROV PHUMPGOV POV PMIL PGOC PRAM PNR PCI PREO POLITICS POLICY PREFA PSI PAIGH PJUS PARMS PROG PTERE PRGOV PORG PS PGOF PKFK PEPR PPA PINT PRELP PNG PFOR PUNE PGOVLO PHUMBA POLINT PGOVE
QA
RIGHTS RU RS RW RIGHTSPOLMIL RICE RUPREL RO RF RELATIONS RP RM RFE REGION REACTION REPORT RCMP RSO ROOD ROBERT RSP
SA SNAR SOCI SENV SZ SP SO SU SF SW SY SMIG SCUL SL SENVKGHG SR SN SARS SANC SHI SIPDIS SEVN SHUM SC SI STEINBERG SK SH SNARCS SPCE SNARN SG SNARIZ SWE SIPRS SYR SYRIA SAARC SEN SCRS SAN ST SSA SPCVIS SOFA
TPHY TSPL TS TRGY TU TI TBIO TH TP TZ TW TX TSPA TFIN TC TAGS TK TIP TNGD TL TV TT TINT TERRORISM TR TN TD TBID TF THPY TO TRSY TURKEY
USEU UK UG UNGA UN UNSC US UZ UY UNHRC UNESCO USTR UNDP UP UNMIK UNEP UNO UNHCR UNAUS UNCHR UNPUOS UNDC UNICEF UNCHC UNCSD USOAS UNFCYP UNIDROIT UV UNCND USNC USUN USPS USAID UE UNVIE UAE UNODC UNCHS UNFICYP UNDESCO UNC
VE VZ VT VM VAT VC VI VTPREL VN VTIZ VTEG
WHO WWARD WTRO WS WHA WIPO WEU WZ WHTI WTO WMO WA WTRQ WBG WFP WB WI WMD WITH
XM XL XV XW XS XA XR XG XB XF XD XK XY XC XZ XX XU XI XT XH XQ XE XTAG
YM YI YE YMCS
ZI ZU ZF ZR ZK ZANU ZB ZEALAND ZP ZO ZL ZOELLICK ZJ ZN ZA

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06OTTAWA2021, POTENTIAL FOR IPR PROGRESS: CANADA'S PROPOSED

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06OTTAWA2021.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06OTTAWA2021 | 2006-06-29 19:57 | 2011-04-28 00:00 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Ottawa

`

    VZCZCXRO5122
    RR RUEHGA RUEHHA RUEHQU RUEHVC
    DE RUEHOT #2021/01 1801957
    ZNR UUUUU ZZH
    R 291957Z JUN 06
    FM AMEMBASSY OTTAWA
    TO RUEHC/SECSTATE WASHDC 3024
    INFO RUCNCAN/ALL CANADIAN POSTS COLLECTIVE
    RUCPDOC/DEPT OF COMMERCE WASHDC

` `

    UNCLAS SECTION 01 OF 02 OTTAWA 002021

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS TO USTR FOR GARDE, ESPINEL, CHANDLER
    STATE PASS TO USDOC FOR GWORD, JBOGER
    STATE PASS TO USPTO FOR MKEPLINGER

    E.O. 12958: N/A
    TAGS: KIPR ECON TBIO CA
    SUBJECT: POTENTIAL FOR IPR PROGRESS:  CANADA'S PROPOSED
    DATA PROTECTION REGULATIONS

    REF: A. OTTAWA 1701

         ¶B. OTTAWA 1317

    ¶1.  (SBU)  Summary:  The GOC has proposed a two-regulation
    package (significantly different from its 2004 proposal)
    consisting of data protection for the innovative
    pharmaceutical industries and "Patented Medicines (Notice of
    Compliance)" for the generic drug industries, a combination
    designed to force compromise between the two sectors.
    Although the innovative pharmaceutical industry organizations
    PhRMA and Rx&D have minor complaints which they hope to have
    addressed in the final regulations (the comment period ends
    July 17), in general the package seems to be a positive
    development for IPR protection in Canada.  In particular, the
    Data Protection regulation is designed to bring Canada into
    compliance with its international obligations to provide
    protection for proprietary data belonging to patent-holding
    companies, something that the Embassy has been encouraging.
    Assuming the proposed rules are finalized, industry observes
    believe that this will be a step forward for Canada's
    protection of IPR and will directly address one complaint
    from the last two Special 301 Reports on Canada.  End Summary.

    The Regulations
    ---------------

    ¶2.  (U)  (SBU)  The Patented Medicines (Notice of Compliance)
    or PMNOC regulation and, to a lesser extent, the Data
    Protection regulation are complex, and we would welcome
    insights from USG experts.  The data protection regulation
    can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle4-e.html
    The PMNOC regulation can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle6-e.html
    Our initial perusal and conversations with contacts have
    provided the following information.

    ¶3.  (SBU) The draft Data Protection regulation stipulates
    that a secondary manufacturer (usually a generic) cannot file
    a new drug submission on the basis of a direct or indirect
    comparison between the new drug and an innovative drug until
    six years after the first notice of compliance was issued to
    the innovator.  The submission will not be approved until at
    least eight years after the first notice of compliance was
    issued.  This data protection period of eight years compares
    favorably to the U.S. "five plus three" period.  (Comment:
    One observer joked to us that now Canada would have better
    data protection than the United States and that the
    innovative industry may start to use this as leverage to
    argue for better data protection in the United States.  End
    comment.)  Both the Canadian industry group Rx&D and PhRMA in
    the United States are preparing comments to submit to Health
    Canada.  From discussions with industry contacts, we believe
    the industry comments will focus on requests for
    clarification, particularly surrounding the transitional
    language that will determine how drug submissions already in
    the pipeline are treated.  A particular point which seems
    unclear to many observers (and of concern to the
    pharmaceutical industry) is paragraph (5) which states that
    the eight year protection period does not apply "if the
    innovative drug is not being marketed in Canada."  We expect
    that the final regulations will clarify how this will be
    applied.  However, the innovative industry's reaction to the
    data protection regulation is positive, with observers
    stating that this will not only bring Canada into compliance
    with its international obligations but will also make the
    country more competitive internationally.
    Qcountry more competitive internationally.

    ¶4.  (SBU)  The Patented Medicines (Notice of Compliance) or
    PMNOC regulation is the part of the package designed to keep
    the generic companies in the deal.  The PMNOC regulation is
    more complex than the data protection regulation, but in
    general it is intended to limit innovative drug companies'
    ability to "evergreen" drug patents, or renew patents based
    on small changes to a drug.  The PMNOC regulation attempts to
    address the unintended consequences of unclear language in
    previous regulation which required court interpretation;
    these include the "possibility that an innovator company may
    delay generic market entry by listing new and sometimes
    irrelevant patents on the basis of minor product revisions."
    In what seems to be a valuable victory for the innovative
    drug industry, however, the PMNOC's Regulatory Impact
    Assessment Statement states that dosage form patents (patents
    that focus on the form of the drug, not its chemical
    composition) deserve "special protection provided by the
    PM(NOC) regulations," adding that this is "particularly true

    OTTAWA 00002021  002 OF 002

    in the case of biologic drugs where effective administration
    of the medicinal ingredient is often dependent on the
    development of new and innovative delivery mechanisms."  The
    generic industry in Canada has not made any public statement
    on the draft regulations, although they will probably submit
    formal comments.  Our contacts also tell us that the generics
    are trying to arrange for meetings with relevant officials
    and members of parliament before the comment period ends on
    July 17.

    GOC Officials' Perspective
    ---------------------------

    ¶5.  (SBU) Our GOC contacts seem confident that these
    regulations will be finalized, with very few changes, in as
    short a period as is possible under Canada's regulatory
    process.  They describe the regulations as fair and balanced,
    and they suggest that neither the innovative nor the generic
    industry should be surprised by the regulations' content.  In
    general, this is what we are hearing from industry contacts
    as well, although industry contacts hesitate to describe
    themselves as happy with the regulations and insist that
    certain changes need to be made.  Any rhetoric about pushing
    for 10 years of data protection such as in Europe seems to be
    more a bargaining tool than an actual goal.  GOC officials
    are aware that both industries, but particularly the
    innovative industry, are eager for a package to be finalized
    and are willing to accept the compromises inherent in these
    proposed regulations.

    Domestic Political Context
    --------------------------

    ¶6.  (SBU) The current Conservative government has been more
    receptive to U.S. concerns about intellectual property
    rights, and domestically the Conservative party is less
    beholden to the generic industry, which is predominantly
    based in the greater Toronto area, a Liberal stronghold.
    (Comment:  a recent bit of much-hyped campaign scandal
    involved questionable donations to a Toronto-area Liberal
    MP--totalling C$54,000--from Apotex Inc's top two executives,
    their wives and six children.  Apotex is Canada's largest
    generic drug company.  End comment.)  The innovative drug
    companies, on the other hand, are primarily based in Quebec,
    where the Conservatives are very interested in picking up
    additional seats.  In general, this suggests that the
    generics industry, which is thought to be responsible for
    delaying progress on the 2004 proposal of the first version
    of these regulations, will not be able to delay progress on
    the new draft regulations.  The most optimistic timeframe for
    final regulations is probably the end of 2006.  As with our
    other IPR goal of amendments to the copyright act, much will
    hinge on whether another election is called in the meantime.
    An election before finalization of the regulations would at
    the very least delay them regulations and could result in yet
    another redraft.

    Visit Canada's Classified Web Site at
    http://www.state.sgov.gov/p/wha/ottawa

    WILKINS

`